No drug is currently approved to treat aging itself, and the most optimistic realistic timeline puts the first one at least a decade away. The biggest obstacle isn’t the science alone. It’s that the FDA doesn’t recognize aging as a disease, which means there’s no regulatory pathway to approve a drug specifically for it. Several promising compounds are in early human trials, though, and a handful are already being prescribed off-label by doctors who aren’t waiting for formal approval.
Why the FDA Is the Bottleneck
For any drug to reach the market, it needs to treat a recognized medical condition. Aging isn’t one. The FDA approves drugs for specific diseases like heart failure, diabetes, or Alzheimer’s, not for the biological process that drives all of them. This creates a strange situation: even if a compound slowed aging across the board, there’s currently no official way to approve it for that purpose.
The FDA has signaled some flexibility. It will consider drugs that target aging mechanisms if sponsors can show effects on specific clinical outcomes, and it’s open to using surrogate endpoints like biomarkers rather than waiting years for hard outcomes like death or disease onset. The agency also has an accelerated approval pathway for drugs where a biomarker is “reasonably likely to predict clinical benefit.” But no one has yet tested this framework with a true anti-aging drug, so the regulatory ground remains unbroken.
This is exactly what one major trial hopes to change.
The TAME Trial: A Regulatory First
The Targeting Aging with Metformin (TAME) trial is designed less as a drug study and more as a legal precedent. Metformin has been used safely for decades to treat type 2 diabetes. The TAME trial plans to enroll over 3,000 adults aged 65 to 79 across 14 research institutions and follow them for six years to see whether metformin delays the onset of heart disease, cancer, and dementia compared to placebo.
If it works, the researchers hope the FDA will create “aging” as an approved indication, essentially opening the door for every anti-aging drug that follows. The trial design has been finalized and a scientific advisory committee is in place, but fundraising has been the persistent challenge. No specific launch date has been publicly confirmed, and the six-year trial clock doesn’t start until enrollment begins. Even in a best-case scenario, results are unlikely before the early 2030s.
Compounds Currently in Human Trials
Rapamycin
Rapamycin is arguably the most reproduced longevity drug in animal research. It works by dialing down a growth-signaling pathway that, when overactive in older age, accelerates cellular wear. The PEARL trial, a phase 2 randomized, placebo-controlled study, enrolled 129 adults aged 50 to 85 and tested weekly doses of rapamycin against placebo over 12 months. The trial is measuring changes in visceral fat, bone density, lean body mass, blood sugar regulation, and cholesterol. Results from this trial will help determine whether the dramatic lifespan extensions seen in mice (where rapamycin is the gold standard) translate to measurable benefits in people.
Some physicians aren’t waiting. A 2022 survey captured self-reported data from 333 adults already taking rapamycin off-label for its potential healthspan benefits. The practice is growing but remains controversial, and safety concerns about long-term use in otherwise healthy people haven’t been resolved by any large trial.
Senolytics
Senolytic drugs work by clearing out “zombie cells,” old cells that stop dividing but refuse to die. These cells accumulate with age and release inflammatory signals that damage surrounding tissue. The most studied senolytic combination pairs two existing compounds (one originally developed for cancer, the other a plant flavonoid). Early human trials have shown it can reduce the burden of these zombie cells in kidney disease patients and improve physical function in people with a serious lung condition called idiopathic pulmonary fibrosis.
A phase 2 trial testing this combination in Alzheimer’s disease is underway. Other trials are targeting osteoarthritis, frailty in older women, and chronic kidney disease. A second senolytic compound, fisetin (found naturally in strawberries and apples), is being tested in at least five separate human trials for conditions ranging from osteoarthritis to frailty. These are all early-stage studies, though. Phase 2 trials typically take two to three years, and phase 3 trials, needed for FDA approval, take longer and are far more expensive. No senolytic is likely to reach the market for a specific age-related disease before the late 2020s at the earliest, and approval for “aging” broadly would take longer still.
NAD+ Boosters
Supplements that raise levels of NAD+, a molecule involved in cellular energy production, have generated enormous consumer interest. NAD+ levels do appear to drop with age, at least in some tissues. The problem is that human trial results have been disappointing so far. A 2025 review in Nature Metabolism concluded that while animal studies looked promising, “human clinical trials have shown limited efficacy.” The evidence for an age-related decline in NAD+ has only been consistently observed in a limited number of studies, and translating results from rodents to people has proven difficult. NAD+ precursors are widely sold as supplements today, but their path to becoming an approved anti-aging drug looks uncertain without stronger clinical data.
Gene Therapy: Promising but Further Out
The most dramatic results in longevity research come from gene therapy, and the most dramatic results are also the furthest from your medicine cabinet. In a landmark mouse study, researchers used a virus-based delivery system to activate telomerase, an enzyme that rebuilds the protective caps on chromosomes. Mice treated at one year old (roughly equivalent to middle age) lived 24% longer. Mice treated at two years old lived 13% longer. Neither group developed more cancer than untreated mice, addressing the longstanding concern that boosting telomerase might fuel tumor growth.
These results remain a proof of concept in animals only. No human trial of telomerase gene therapy for aging has been completed. The delivery technology, using adeno-associated viruses, has an established safety profile in other gene therapies and is already FDA-approved for conditions like spinal muscular atrophy. But designing, testing, and approving a gene therapy for aging in humans would require clearing both the scientific and regulatory hurdles simultaneously. This is plausibly a 2040s prospect, not a 2030s one.
The Measurement Problem
One reason anti-aging drugs are taking so long is that researchers still don’t fully agree on how to measure whether they’re working. You can’t run a trial that waits 30 years to see if people live longer. Instead, trials need reliable stand-in measurements.
Epigenetic clocks, which estimate biological age by reading chemical patterns on DNA, have become the most popular approach. Other biomarkers track the inflammatory signals released by zombie cells or measure proteins associated with specific diseases like Alzheimer’s. The FDA has a formal process for qualifying biomarkers as acceptable stand-ins for clinical outcomes, but no aging biomarker has been officially qualified yet. Until one is, every trial faces the challenge of proving its measurements actually predict the thing that matters: whether people stay healthier longer.
What’s Available Now (Off-Label)
If you’re searching for anti-aging drugs, you’ve likely already encountered the off-label market. Metformin and rapamycin are both FDA-approved for other conditions and can legally be prescribed by a physician for longevity purposes. Metformin is more commonly used this way because it’s inexpensive, widely available, and perceived as very safe. Rapamycin use is growing but carries more concern about immune suppression and side effects at higher doses.
Neither drug has been proven to extend human lifespan in a controlled trial. People taking them are essentially running their own experiment, guided by animal data and early human signals but without the kind of evidence the FDA would require. NAD+ precursors and fisetin are available without a prescription as dietary supplements, but supplements face no requirement to prove they work before being sold.
A Realistic Timeline
The first drug approved specifically for an age-related indication with a geroscience framing (targeting the biology of aging rather than a single disease) could arrive in the early to mid-2030s. That would most likely be a senolytic approved for a specific condition like osteoarthritis or pulmonary fibrosis, or metformin if the TAME trial succeeds and the FDA creates an aging indication. A true “anti-aging pill” approved to slow aging in healthy people is further out, probably 15 to 20 years at minimum, because the trials needed to prove that claim are enormous and the regulatory framework doesn’t yet exist.
The more likely near-term scenario is a patchwork: drugs approved for individual age-related diseases that happen to work by targeting aging biology, prescribed increasingly off-label by physicians who connect the dots before regulators do. For people hoping to benefit from these advances, the practical reality is that the science is closer than the system built to deliver it.